To investigate how proteostasis changes in disease, we crossed Fluc‐EGFP mice to the rTg4510 line, a double‐transgenic tauopathy model where expression of the responder transgene containing human four‐repeat tau with the familial P301L mutation (tetO‐tauP301L) is controlled by the CaMKIIα‐tTA activator transgene. Here, MAPT is linked to tauopathy.